Apoptosis related microRNAs and MGMT in glioblastoma cell lines submitted to treatments with ionizing radiation and temozolomide

“…Group treated with ionizing radiation (R): 10 5 were seeded 24 hours before treatment with ionizing radiation, with a dose rate of 2.0 Gy/min, (60Co source, Unit Gammatron S-80, Siemens, 1.25 MeV, HC-FMRP/USP), for a total dose of 14 Gy. Collection occurred 48 hours after treatment [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

Expression of microRNAs miR-21 and miR-326 associated with HIF-1α regulation in neurospheres of glioblastoma submitted to ionizing radiation treatment

Turra

Rodrigues

Neto

et al. 2022

Rep Pract Oncol Radiother.

Self Cite

View full text Add to dashboard Cite

show abstract

“…MGMT is expressed in approximately 55% of GBM patients, rendering temozolomide and other DNA alkylating agents ineffective. Since neither U87 nor U251 cells express MGMT protein, we anticipated that temozolomide would decrease the viability of U251 and U87 cells in a dose-dependent manner (Trevisan et al [52]; Yi et al [60,61]). However, we found that the cell viability of U87-luc2 cells was minimally decreased 72 h after exposure to 500 µM TMZ; the cell viability of U251-RedFluc cells was minimally decreased after 48 and 72 h after exposure to 500 µM TMZ (Fig.…”

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

Characterization and comparison of human glioblastoma models

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is one of the deadliest cancers. Treatment options are limited, and median patient survival is only several months. Translation of new therapies is hindered by a lack of GBM models that fully recapitulate disease heterogeneity. Here, we characterize two human GBM models (U87-luc2, U251-RedFLuc). In vitro, both cell lines express similar levels of luciferase and show comparable sensitivity to temozolomide and lapatinib exposure. In vivo, however, the two GBM models recapitulate different aspects of the disease. U87-luc2 cells quickly grow into large, well-demarcated tumors; U251-RedFLuc cells form small, highly invasive tumors. Using a new method to assess GBM invasiveness based on detecting tumor-specific anti-luciferase staining in brain slices, we found that U251-RedFLuc cells are more invasive than U87-luc2 cells. Lastly, we determined expression levels of ABC transporters in both models. Our findings indicate that U87-luc2 and U251-RedFLuc GBM models recapitulate different aspects of GBM heterogeneity that need to be considered in preclinical research.

show abstract

“…Targeting the corresponding proteins and genes decreased cell proliferation, metastasis, invasion, and glioblastoma (GBM) cell's apoptotic cycle, demonstrating their efficiency (apoptotic pathways). In addition, therapeutic pathways mediate temozolomide resistance and trigger cell cycle apoptosis, as proven by six studies (Xu et al, 2018;Cui et al, 2020;Trevisan et al, 2020;Forte et al, 2019;Vengoji et al, 2019;Avci et al, 2020). Mitogen-activated protein kinases (MAPK) have been identified as a signaling mechanism in cancer development.…”

Section: Glioblastoma (Gbm)mentioning

confidence: 99%

“…receptor pathways (D. H.Lee et al, 2014),(Wang et al, 2017),(Kaushik et al, 2020) Epidermal growth receptor pathways(Lei et al, 2017), (P Xu et al, 2018(Pall et al, 2019), (Mai et al, 2017,(Trevisan et al, 2020),(Vengoji et al, 2019) Mitochondrial pathways(Silva et al, 2019),(Cui et al, 2020), (T. J.Lee et al, 2017), (Pareja et al, 2014,(Yin Xu et al, 2010),(Zappavigna et al, 2016),(Cheng et al, 2020) ,(Kusaczuk et al, 2018), (Avci et al, 2020,(Maria Forte et al, 2019) (Yang Xu et al, 2020 …”

mentioning

confidence: 99%

Therapeutic Targeting on Death Pathways in Glioblastoma

2022

J Angiotherapy

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a type of aggressive glioma composed of star-shaped glial cells; it is also known as grade IV astrocytoma. Alterations are enhancing therapeutic effectiveness for individuals with glioblastoma to several targeted medicines that target cell death pathways such apoptosis (type I), autophagic cell death (type II), and necrosis (type III). The purpose of this review was to compile information about the various methods of killing cancer cells in glioblastoma and the treatments currently being used. This review aimed to determine the effectiveness of targeted therapy on glioblastoma death pathways, both intrinsic and extrinsic. Furthermore, nanoparticles studies represented a significant advance in glioblastoma via combinatorial therapy. Targeting specific proteins or genes using drug-loaded nanoparticles has promise as a treatment for glioblastoma.

show abstract

Apoptosis related microRNAs and MGMT in glioblastoma cell lines submitted to treatments with ionizing radiation and temozolomide

Cited by 4 publications

References 30 publications

Expression of microRNAs miR-21 and miR-326 associated with HIF-1α regulation in neurospheres of glioblastoma submitted to ionizing radiation treatment

Expression of microRNAs miR-21 and miR-326 associated with HIF-1α regulation in neurospheres of glioblastoma submitted to ionizing radiation treatment

Characterization and comparison of human glioblastoma models

Therapeutic Targeting on Death Pathways in Glioblastoma

Contact Info

Product

Resources

About